Mer­ck adds an­oth­er OK to Keytru­da score­board; Arde­lyx, Ky­owa Kirin broad­ens part­ner­ship be­yond tena­panor

Mer­ck‘s an­ti-PD-1 block­buster, Keytru­da, is rack­ing up win af­ter win. The newest jew­el to the crown for the com­pa­ny is the Chi­nese ap­proval of the ther­a­py in com­bi­na­tion with car­bo­platin and pa­cli­tax­el for the first-line cas­es of metasta­t­ic squa­mous non-small cell lung can­cer (NSCLC). With this new in­di­ca­tion, Keytru­da is now ap­proved to treat both squa­mous and non-squa­mous NSCLC in con­junc­tion with chemother­a­py, as well as a sub­group of NSCLC pa­tients as a monother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.